Sanofi wins first dengue vaccine market approval in Mexico

An article from Reuters
December 9, 2015
Sanofi's dengue vaccine is to make its market debut in Mexico, the French drugmaker said on Wednesday, adding that it expects to have filed for market approval in some 20 countries by year-end.
 
Sanofi Pasteur, the group's vaccines division, said Mexico had approved the preventive treatment, called Dengvaxia, for all four dengue virus serotypes, but only for patients aged 9 to 45 who live in areas where the disease is endemic.
 
This means the world's first dengue vaccine has no approval yet for use on young children, a population considered to be most at risk, or for use by tourists.
 
Dengue fever is a mosquito-borne disease caused by four virus serotypes (1 to 4) as categorized by the World Health Organisation. Overall, the disease is seen as a threat to about half of the world's population. Some 400 million people are believed to be infected annually.
 
Read more here
Common Disease Taxonomy: 
0